Latest Headlines

  1. VedTechBio Unveils Next-Gen Drug Discovery AI; Partners With AlphaMeld In Multi-Therapy Collaboration 7/31/2025

    VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug discovery timelines in half alongside a strategic collaboration with AlphaMeld Corporation to co-develop multiple therapies for metabolic and rare diseases.

  2. Altasciences And VoxCell BioInnovation Announce Strategic Collaboration To Advance Preclinical Drug Development 7/31/2025

    Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials.

  3. Felycin-CA1 (Sirolimus Delayed-Release Tablets) Is The First And Only Drug FDA Approved For The Management Of Ventricular Hypertrophy In Cats With Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting As Many As One In Seven Cats 7/30/2025

    PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide.

  4. Actio Biosciences Announces U.S. FDA Clearance Of Investigational New Drug Application And Fast Track Designation For ABS-1230, A KCNT1 Inhibitor For The Treatment Of KCNT1-Related Epilepsy 7/30/2025

    Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application and granted Fast Track designation for ABS-1230, an expected first-in-class, orally administered small molecule KCNT1 inhibitor, for the treatment of KCNT1-related epilepsy.

  5. EuMentis Therapeutics Receives U.S. FDA Clearance Of IND Application For EM-221, A Novel PDE10A Inhibitor For Schizophrenia 7/30/2025

    EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia.

  6. BON Launches AI-Powered New Drug Research And Development 7/30/2025

    Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business.

  7. BioDuro And Atombeat Announce Partnership To Launch An AI-Powered Platform For Accelerated Peptide Drug Discovery 7/30/2025

    BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), and Atombeat Inc., a leading force in AI for drug discovery, today announced a strategic collaboration to an AI powered platform for accelerated peptide drug discovery.

  8. Announces That The European Medicines Agency Has Granted Orphan Drug Designation To Nuvisertib (TP-3654) For The Treatment Of Myelofibrosis 7/30/2025

    Sumitomo Pharma America, Inc. (SMPA) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to nuvisertib (TP-3654), an oral investigational highly selective inhibitor of PIM1 kinase, for the treatment of patients with myelofibrosis (MF).

  9. Alpha Cognition Announces Partner China Medical System Has NDA Accepted In China For The Review Of ZUNVEYL (Benzgalantamine) For Alzheimer's Disease 7/29/2025

    Alpha Cognition Inc. (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer’s dementia.

  10. Transforming Drug Development With Groundbreaking Organ-On-Chip Tech 7/29/2025

    An international team of researchers supported by the EU-funded UNLOOC(opens in new window) project is developing organ-on-chip (OOC) systems that simulate human organ responses, providing faster, safer and more reliable drug testing alternatives.